✦ LIBER ✦

Suboptimal response in chronic myeloid leukemia patients treated with imatinib: Early identification and new therapeutic challenges

✍ Scribed by Massimo Breccia; Giuliana Alimena

Book ID: 118208794
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 190 KB
Volume: 325
Category: Article
ISSN: 0304-3835
DOI: 10.1016/j.canlet.2012.05.032

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Predictive factors for successful imatin

Predictive factors for successful imatinib cessation in chronic myeloid leukemia patients treated with imatinib

✍ Lee, Sung-Eun; Choi, Soo Young; Bang, Ju-Hee; Kim, Soo-Hyun; Jang, Eun-jung; Bye 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 598 KB

Excellent therapeutic results achieved i

Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: A retrospective study on 91 unselected patients

✍ Cerrano, Marco; Crisà, Elena; Pregno, Patrizia; Aguzzi, Chiara; Riccomagno, Paol 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB

EUTOS score predicts survival and cytoge

EUTOS score predicts survival and cytogenetic response in patients with chronic phase chronic myeloid leukemia treated with first-line imatinib

✍ Tao, Zhongfei; Liu, Bingcheng; Zhao, Yaozhong; Wang, Ying; Zhang, Rongli; Han, M 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 621 KB

Mean cell volume can be an early predict

Mean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?

✍ Moo-Kon Song; Joo-Seop Chung; Young-Mi Seol; Seong-Geun Kim; Ho-Jin Shin; Young- 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 249 KB

Imatinib-induced macrocytic anemia was known to result from c-kit inhibition in chronic myeloid leukemia (CML). However, recent studies showed that the prevalence of anemia is increased with high trough imatinib level and increased doses of imatinib influence decreased proliferation of burst forming

Early and tardive skin adverse events in

Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib

✍ M. Breccia; I. Carmosino; E. Russo; S. G. Morano; R. Latagliata; G. Alimena 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

BCR-ABL gene amplification and overexpre

BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib

✍ Dorothea Gadzicki; Nils von Neuhoff; Doris Steinemann; Marianne Just; Guntram Bü 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 297 KB